Table 4 Grade 3/4 non-serious adverse events
From: A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
Grade 3 | Number of patients and percentage |
|---|---|
Anaemia | 2/15, 13.3% |
Stomatitis | 2/15, 13.3% |
Fatigue | 2/15, 13.3% |
Platelet count decrease | 1/15, 6.7% |
Constipation | 1/15, 6.7% |
Gamma-glutamyltransferase increase | 1/15, 6.7% |
Proteinuria | 1/15, 6.7% |
Grade 4 | |
Anaemia | 1/15, 6.7% |
Platelet count decrease | 1/15, 6.7% |